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Abstract
Background: Expanding antimicrobial resistance patterns in the face of stagnant growth in novel antibiotic
production underscores the importance of antibiotic stewardship in which de-escalation remains an integral
component. We measured the frequency of antibiotic de-escalation in a tertiary care medical center with an
established antimicrobial stewardship program to provide a plausible benchmark for de-escalation.
Methods: A retrospective, observational study was performed by review of randomly selected electronic medical
records of 240 patients who received simultaneous piperacillin/tazobactam and vancomycin from January to
December 2011 at an 885-bed tertiary care medical center. Patient characteristics including antibiotic regimen,
duration and indication, culture results, length of stay, and hospital mortality were evaluated. Antibiotic de-
escalation was defined as the use of narrower spectrum antibiotics or the discontinuation of antibiotics after
initiation of piperacillin/tazobactam and vancomycin therapy. Subjects dying within 72 h of antibiotic initiation
were considered not de-escalated for subsequent analysis and were subtracted from the study population in
determining a modified mortality rate.
Results: The most commonly documented indications for piperacillin/tazobactam and vancomycin therapy were
pneumonia and sepsis. Of the 240 patients studied, 151 (63%) had their antibiotic regimens de-escalated by 72 h.
The proportion of patients de-escalated by 96 h with positive vs. negative cultures was similar, 71 and 72%,
respectively. Median length of stay was 4 days shorter in de-escalated patients, and the difference in adjusted
mortality was not significant (p = 0.82).
Conclusions: The empiric antibiotic regimens of approximately two-thirds of patients were de-escalated by 72 h in
an institution with a well-established antimicrobial stewardship program. While this study provides one plausible
benchmark for antibiotic de-escalation, further studies, including evaluations of antibiotic appropriateness and
patient outcomes, are needed to inform decisions on potential benchmarks for antibiotic de-escalation.
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Background
Antimicrobial resistance continues to increase at alarm-
ing rates. Moreover, the rate at which new, novel anti-
microbial agents have been developed and approved for
therapy of infections has considerably decreased.
Consequently, efforts to promote judicious and appro-
priate use of antibiotics are of significant importance.
Antibiotic de-escalation, in which broad, empiric
antimicrobial therapy is either discontinued or replaced
with a narrowed spectrum antibiotic, has been an area
of increasing focus for decreasing or improving
antibiotic use [1–4].
Studies have demonstrated that antibiotic de-escalation
is safe and not associated with poorer outcomes [3–12].
Anticipated benefits of de-escalation include an improve-
ment in antibiotic resistance profiles and a reduction of
antibiotic-related adverse events. Furthermore, the current
Infectious Diseases Society of America antimicrobial
stewardship guidelines recommend the streamlining and
de-escalation of empirical antimicrobial therapy based on
culture results to more effectively target the causative
pathogen, thereby resulting in decreased antimicrobial ex-
posure and substantial cost savings [13].
The practice of antibiotic de-escalation is not
standardized, and several barriers to antibiotic de-
escalation have been reported. These barriers include
complex sensitivity patterns of the offending organ-
ism, inconclusive microbiological data, colonization
with multi-drug resistant pathogens, and receipt of
previous antibiotic therapy [14]. Other studies have
described factors related to providers’ clinical
decision-making as key barriers to de-escalation.
These factors include a lack of diagnostic facility, a
lack of multidisciplinary collaboration, a lack of edu-
cation among junior prescribers, and reluctance to
de-escalate antibiotics in critically ill patients who are
improving with broad spectrum therapy [15–17].
The frequency with which antibiotic regimens are de-
escalated or should be de-escalated in the hospital set-
ting is not well described. The few studies that are avail-
able suggest a variable frequency of antibiotic de-
escalation which ranges from 10 to 70% [14, 18]. Fur-
thermore, the majority of studies of antibiotic de-
escalation are limited to the intensive care setting and
often to one disease entity such as ventilator associated
pneumonia [1–12]. The frequency of hospital-wide
antibiotic de-escalation in a setting with an established
stewardship program has not been described. Thus, the
purpose of this study was to measure the frequency of
antibiotic de-escalation for one commonly used combin-
ation of empiric antibiotic therapy in an academic,
tertiary care medical center with an established anti-
microbial stewardship program (ASP) in order to
describe a plausible de-escalation benchmark.
Methods
Study design
The study took place at Wake Forest Baptist Medical
Center (WFBMC), an 885-bed tertiary care referral center
with an active ASP. A list of 2,937 candidate patients ≥18
years of age was generated through a pharmacy database
identifying inpatients who were prescribed the simultan-
eous combination of intravenous piperacillin/tazobactam
and vancomycin from January to December 2011. This
particular combination of antibiotics was used as inclusion
criteria because in antibiotic utilization reports in previous
years, it represented the most common broad spectrum
empiric antibiotic regimen prescribed in the inpatient
setting at WFBMC.
A sample of 20 patients per month was randomly se-
lected from the candidate list using an online random
number generator. If a study patient was admitted and ini-
tiated on piperacillin/tazobactam and vancomycin twice
within the same month, only data from the first hospital
admission was considered. Patients were stratified by
month to account for seasonal variability in antibiotic use
and inpatient prescriber differences. A retrospective chart
review of the electronic medical record was subsequently
performed on the selected patients.
Data collected included age, sex, hospital service, attend-
ing physician, documented indication for antibiotics, num-
ber of days on piperacillin/tazobactam and vancomycin, de-
escalated antibiotic regimens, culture data, radiographic
diagnoses, occurrence of antibiotic de-escalation at 24, 48,
72 and 96 h time points, length of stay, final clinical
diagnosis, continuation of antibiotics after discharge, and in-
hospital mortality. The primary outcome assessed was the
frequency of antibiotic de-escalation at 72 h.
Antibiotic de-escalation in patients with both positive
and negative bacterial cultures was quantified in order
to evaluate the impact of culture data on the frequency
of antibiotic de-escalation. Antibiotic de-escalation at
96 h was assessed to account for clinical decision mak-
ing that may have occurred using culture data at 72 h
incubation.
Definitions
Antibiotic de-escalation was defined as the use of nar-
rower spectrum antibiotics or the discontinuation of anti-
biotics after initiation of broad spectrum empiric
antibiotic therapy. An antibiotic regimen change that re-
sulted in narrowed coverage of a group of pathogens, yet
also expanded coverage to include an additional group of
pathogens, was not considered to represent an antibiotic
de-escalation event. For example, while excluding anti-
pseudomonal therapy, a transition from piperacillin/tazo-
bactam to ertapenem was not considered a de-escalation
event, as coverage of extended spectrum beta-lactamase
producing organisms was incorporated. Similarly, an
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antibiotic change of one broad-spectrum class to another
was not considered a de-escalation event. For example, if
piperacillin/tazobactam was changed to cefepime, this was
not considered to represent de-escalation even though an-
aerobic activity was dropped.
Similar to how previous studies have analyzed patients
who were lost to follow up, patients were evaluated in
the context of the unfavorable outcome group. There-
fore, patients who expired within 72 h of initiation of
broad spectrum antibiotics were considered not eligible
for de-escalation and were therefore analyzed as not
having their antibiotics de-escalated. These patients were
subsequently excluded from analysis in determining a
modified mortality rate. Patients who were discharged
within 72 h had their antibiotic regimens analyzed
analogous to those admitted for longer than 72 h.
The indication for antibiotic therapy was ascertained
from documentation in the electronic medical record by
the primary team at the time of simultaneous piperacil-
lin/tazobactam and vancomycin use. Sepsis was recorded
as the indication for antibiotics in patients who either
had “sepsis” or “SIRS” documented in their medical rec-
ord as the reason for initiation of antibiotics. Sepsis as a
consequence of a known source (e.g. pneumonia) was
considered as the source infection and not sepsis. Pa-
tients who had defined microbiological data from any
source were considered to have positive cultures.
Description of Antibiotic Stewardship Program
The ASP at WFBMC had been in place for 11 years at
the time of the study. The core team consisted of two
Infectious Diseases (ID) physicians acting as primary
and associate medical directors, two ID PharmDs, an ID
PharmD administrator, and an ID Pharmacy resident.
The main components of the program during this entire
time period were prospective audit and feedback (PAF)
and preauthorization for selected antimicrobials. PAF
was conducted 3 times per week by an ID PharmD in
which patients were identified by an informatics gener-
ated list of positive sterile body fluids, use of selected an-
timicrobials, diagnosis of a selected infection, or referral
by another clinical ward PharmD. Identified patient re-
cords were examined and improvements in antibiotic
use were communicated back to the prescribing phys-
ician by phone. Antibiotic de-escalation, if appropriate,
would be suggested at that time. The emphasis of PAF
varied over the time period of the study depending on
the ASP priority needs for intervention.
Antibiotics that had been selected for PAF at least one
time during the period before or during the study
included carbapenems, linezolid, aztreonam, oral vanco-
mycin, and intravenous fluoroquinolones. Intravenous
vancomycin or piperacillin/tazobactam was not selected
for PAF specifically, but may have been included in an
intervention when they were used for a scrutinized in-
fection, or by other PharmD referral. Broad spectrum
antibiotics that required pre-authorization included
carbapenems, aztreonam, ceftazidime, linezolid, and
daptomycin, but not cefepime, vancomycin or piperacil-
lin/tazobactam.
De-escalation interventions other than PAF included
ASP team suggestions for subsequent de-escalation at
the time of pre-authorization, review of antibiotics by
the ASP team or other clinical PharmD at the time of
patient transfer (particularly intensive care unit transfer
to the ward), ward or intensive care unit (ICU) clinical
PharmD suggestion during daily rounds, quarterly
housestaff case-based education, and ongoing provider
education in large group presentations or at departmen-
tal meetings. Automatic stop orders or formal antibiotic
“time-outs” were not used. Electronic medical record
clinical decision support is not a component of the ASP,
but electronic order sets that include antibiotics are
available for commonly encountered infections. Local
guidelines are available on the ASP website.
Statistical analysis
Odds Ratios with 95% confidence intervals were calcu-
lated to determine differences between groups of categor-
ical data. Quantile regression was performed to evaluate
differences in hospital length of stay between patients
whose antibiotics were de-escalated and not de-escalated.
Results
Data was collected from 240 patients who were treated
with the simultaneous combination of piperacillin/tazo-
bactam and vancomycin during the study period. Patient
age ranged from 19 to 94 years with a median age of
64 years. Antibiotic regimens were de-escalated in 151
(63%) and 175 (73%) patients by 72 and 96 h, respectively.
At 24, 48, 72, and 96 h, the percentage of patients who
did not have their antibiotics de-escalated was 62, 43,
37, and 27% respectively. Of the patients whose anti-
biotic regimen was de-escalated, the greatest proportion
occurred in the 0–24 h time period. Successive 24-h
time increments reveal less dramatic proportions of de-
escalation.
Antibiotic disposition at 72 h among patients who had
their antibiotics de-escalated was heterogeneous (Fig. 1).
Notably, for 79 (52%) patients who had their antibiotics
de-escalated, vancomycin was discontinued and pipera-
cillin/tazobactam was changed to an antibiotic with a
narrowed spectrum. The most common antibiotics that
were prescribed for de-escalation from piperacillin/tazo-
bactam were moxifloxacin and ceftriaxone. Thirty-nine
(26%) patients had their antibiotic therapy completely
discontinued.
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The most commonly documented indications for initi-
ation of broad spectrum antibiotics were pneumonia,
sepsis, and skin and soft tissue infections (Table 1). We
observed the lowest de-escalation rates for skin and soft
tissue infections (44%). While all other indications
showed higher de-escalation rates, the difference was
only statistically significant for urinary tract infections,
Odds Ratio = 18.8 (95% CI: 2.2 – 162.9).
Overall, 234 patients (98%) in the study population had
microbiologic culture specimens obtained during their
hospitalization. Of those, 94 (40%) patients had positive
culture results. Antibiotic regimens were de-escalated by
96 h in 67 (71%) patients with positive culture results and
in 101 (72%) patients with negative culture results. This
difference was not statistically significant. A subsequent
analysis was performed on patients with positive cultures
whose regimens were not de-escalated (n = 27). Of these,
17 (63%) patients would have been appropriate for de-
escalation based on their defined microbiologic data. Eight
(30%) patients would have not been appropriate for de-
escalation, and two (7%) died within 24 h, and conse-
quently, would not have been eligible.
Patients admitted to oncology services had a higher
frequency (71 vs. 63%) of antibiotic de-escalation at 72 h
compared to the study population as a whole, although
this was not statistically significant. Patients admitted to
the remainder of services, including critical care units,
had a similar frequency of antibiotic de-escalation to
that observed in the overall study population (Table 2).
The two most common documented indications for em-
piric vancomycin and piperacillin/tazobactam on critical
care compared to oncology services were sepsis and pneu-
monia, and fever and pneumonia respectively (41 and 34
vs. 38 and 24%). Among other services, pneumonia and
sepsis were the most common (41 and 23% respectively).
The median length of stay was 4 days shorter in pa-
tients who had their antibiotics de-escalated compared
to those who did not (6 vs.10 days), p = 0.0003. One
hundred fourteen (48%) patients were discharged home
on antibiotics. The median length of stay for those pa-
tients was 5 days as compared to 9 days for those who
were not discharged on antibiotics, p = 0.01.
Thirty-four (14%) study patients experienced in-
hospital mortality. Mortality rates were significantly
lower among patients who had their antibiotic regimens
de-escalated compared to patients who did not, p =
0.002, Mortality Odds Ratio = 0.31 (95% CI: 0.14–0.65).
However, 12 patients expired within 72 h of initiation of
piperacillin/tazobactam plus vancomycin and were not
eligible to have their antibiotic regimen de-escalated at
72 h. Therefore, a secondary analysis or modified mor-
tality rate was also calculated to account for the impact
these patients would have on the difference in mortality
rates between groups (Table 3). In this analysis, only pa-
tients who were still living at 72 h were considered and
no significant difference in mortality was observed be-
tween those whose antibiotic regimens were de-
escalated and those whose regimens were not, Modified
Mortality Odds Ratio = 0.84 (95% CI: 0.34–2.05).
Discussion
This study of antibiotic de-escalation for one of the most
commonly prescribed broad spectrum antibiotic regi-
mens for empiric therapy, vancomycin plus piperacillin/
tazobactam, showed that the majority of patients,
approximately two-thirds, had their antibiotic regimens
de-escalated by 72 h in a single institution with a well-
Fig. 1 Disposition of piperacillin/tazobactam and vancomycin therapy
at 72 h in patients who had their antibiotic regimens de-escalated





n = 240 (%)
Patients with regimen
de-escalated by 72 h
for each indication
n = 151 (%)
Odds Ratio
(95% CI)
Pneumonia 91 (38) 57 (63) 2.1 (0.9–5.0)
Sepsis 64 (27) 39 (61) 2.0 (0.8–4.9)
Skin or Soft
Tissue Infection
27 (11) 12 (44) Ref
Fever 23 (10) 14 (61) 1.9 (0.6–6.0)
Urinary Tract
Infection
16 (6) 15 (94) 18.8 (2.2–162.9)
Other 19 (8) 14 (74) 3.5 (1.0–12.5)





n = 240 (%)
Critical Care
n = 58 (%)
Oncology
n = 21 (%)
Other
n = 161 (%)
24 90 (38) 28 (48) 5 (24) 57 (35)
48 136 (57) 31 (53) 9 (43) 96 (60)
72 151 (63) 36 (62) 15 (71) 100 (62)
96 175 (73) 40 (69) 17 (81) 118 (73)
Odds Ratio
(95% CI) at 72 h
N/A 0.7 (0.2–1.9) Ref 0.7 (0.2–1.8)
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established and resourced ASP. In addition, over half of
patients had their regimens de-escalated by 48 h. The
high proportion of patients de-escalated from the study
antibiotics was reflected across a range of clinical ser-
vices and presenting infections.
While the frequency with which hospital-wide antibiotic
de-escalation occurs is not well-described in the literature,
published estimates of antibiotic de-escalation are widely
variable and range from 10 to 70% [14, 18]. In our study,
antibiotic de-escalation occurred in nearly two-thirds of
patients by 72 h. As antibiotic de-escalation is a key
function of ASPs, including ours, the presence of an
established ASP may facilitate higher rates of antibiotic
de-escalation [19, 20]. Consequently, the frequency of de-
escalation observed in this study is likely higher than that
of a medical center that does not have an established ASP.
Importantly, our study does not provide a measure of ef-
fectiveness of our ASP or compare the frequency of anti-
biotic de-escalation before-and-after the establishment of
the ASP at our institution. Rather, it measures hospital-
wide antibiotic de-escalation to provide a plausible bench-
mark for institutions with a multi-disciplinary ASP utilizing
prospective audit and feedback and prior authorization as its
core components.
Previous studies on antibiotic de-escalation are
largely confined to the intensive care setting, are
disease-specific, and highlight that de-escalation is
safe and is not associated with worse outcomes. For
example, in a randomized, prospective trial of 81 in-
tensive care unit (ICU) patients with ventilator-
associated pneumonia (VAP), Singh et al. found that
patients whose antibiotic regimens were de-escalated
were less likely to develop antibiotic resistant super-
infections compared to those whose regimen was not
de-escalated (15 vs 35%, p = 0.017) [1]. Similarly, a
2007 observational, prospective study involving 143
patients with VAP demonstrated decreased mortality
at day 15 (5 vs 32%) and day 28 (12 vs. 44%) with
shorter ICU and hospital stays in patients whose anti-
biotic regimens were de-escalated [2].
A number of study observations warrant further discus-
sion. First, patients admitted to oncology services were
observed to have the highest frequency of antibiotic de-
escalation. While the high proportion of de-escalation in
this population is surprising, the oncology patients cap-
tured in this study comprised a minority of the study
population and cefepime, not piperacillin/tazobactam,
plus/minus vancomycin, were the fever-neutropenia
protocol indicated antibiotics. Although fever was the
most common documented indication for broad spectrum
antibiotics on oncology services, only two of these patients
had concurrent neutropenia documented. Additionally,
while hyperpyrexia in immunocompromised patients may
have led prescribers to utilize empiric broad spectrum
antimicrobial therapy, they were also quick to de-escalate
therapy which may reflect recognition of limited instances
where anti-MRSA therapy was indicated, even if broad
spectrum gram negative coverage was.
Next, we did not observe significant differences in the
proportion of patients de-escalated when they were
stratified according to the documented indication for an-
tibiotics, with the exception of urinary tract infections.
The higher frequency of antibiotic de-escalation in pa-
tients with urinary tract infections (94%) compared to
the overall study population is likely related to several
different factors. First, patients with urinary tract infec-
tions represented a very small percentage of the total
study population (7%). Additionally, piperacillin/tazobac-
tam plus vancomycin is not a regimen that is typically
used for the empiric treatment of urinary tract infec-
tions. Thirdly, culture results are often available for these
patients by 48 h. Thus, prescribers are likely to de-
escalate these regimens quickly.
The vast majority of patients in our study had culture
data available to assist prescribers with decision-making.
However, no appreciable difference was observed in the
frequency of de-escalation between patients who had
positive cultures when compared to patients with nega-
tive cultures (71 and 72% respectively). While the major-
ity of patients with positive cultures were de-escalated, a
secondary analysis of patients with positive cultures
whose regimens were not de-escalated revealed that 17
(63%) would have been appropriate for de-escalation
based on defined microbiologic isolates. In most cases,
the presence of culture data, either positive or negative,
may facilitate de-escalation of antibiotic therapy, but fur-
ther study is needed to determine how clinicians use
culture data in their de-escalation practice. While posi-
tive cultures can define microbiology and allow pre-
scribers to tailor antibiotic regimens to the isolated
organisms, negative cultures may provide reassurance
for prescribers as they de-escalate antibiotic regimens.
The ultimate decision to de-escalate therapy is likely in-
fluenced by an interplay of dynamic clinical variables














Mortality 13 (9) 21 (24) 0.31 (0.14–0.65) 0.002
Modified
Mortalitya
13 (9) 9 (10) 0.84 (0.34–2.05) NS
Median Length
of Stayb(days)
6 10 N/A 0.0003
aModified Mortality: considers only patients who survived past day 3 and were
subsequently eligible for antibiotic de-escalation at 72 h
bOverall Median LOS was 7 with an Interquartile Range of 4–13
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that may be further compounded by severity of illness
and complex susceptibility patterns.
Another interesting finding is the large proportion of
patients whose antibiotic regimen was de-escalated
within 24 h. The decision to de-escalate in this time-
frame is likely not based on culture results, but instead
on the patient’s clinical status and the decision that the
patient’s clinical picture did not warrant the use of broad
spectrum antimicrobial therapy.
Finally, observed mortality rates and hospital length of
stay were both lower in patients who had their antibi-
otics de-escalated compared to those who did not. How-
ever, these associations may be surrogate markers of
overall clinical status and the severity of illness, which
were not controlled for in this study. Nevertheless, our
data highlights that de-escalation was not associated
with an increase in mortality.
Limitations of this study include the retrospective
study design and the reliance on medical record docu-
mentation for data collection, including the indications
for empiric vancomycin and piperacillin/tazobactam.
Certain patient populations were also under-represented
in this study, such as oncology patients and patients with
urinary tract infections. This study measured the fre-
quency of antibiotic de-escalation at a single center with
an established ASP, and as a result, may not be applic-
able to all institutions. Additionally, only patients who
were empirically started on piperacillin/tazobactam and
vancomycin were included in the study. Consequently,
we did not measure all antibiotic de-escalation that may
have occurred during the study period and frequency of
de-escalation may differ for other broad spectrum em-
piric antibiotic regimens. Finally, this study did not
evaluate the appropriateness of antibiotics including
both empiric and de-escalated regimens.
Conclusions
De-escalation of empiric antibacterial therapy is increasingly
recognized as an important principle of antibiotic steward-
ship. While antibiotic de-escalation may not be feasible or
appropriate in every instance, this study adds to the litera-
ture as potential benchmarks for antibiotic de-escalation are
being considered. Future studies should examine the fre-
quency of antibiotic de-escalation at other institutions both
with and without established ASPs. In addition, longitudinal
comparisons of the frequency of antibiotic de-escalation
may add important information on whether frequencies
change over time at a given institution. While our study
measured the frequency of antibiotic de-escalation, we did
not assess appropriateness of either the empiric or de-
escalated antibiotic regimen. Interpreting the occurrence of
antibiotic de-escalation in the context of appropriateness
would assist in determining whether a 72-h antibiotic de-
escalation frequency of 60–70% is a reasonable benchmark.
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